Co-Diagnostics, Inc.

CODX Nasdaq SEC CIK 1692415
Follow Co-Diagnostics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $282.9K +94.6% vs same quarter last year
Net income −$6.3M −7.1% vs same quarter last year
EPS, diluted −$1.01 +78.3% vs same quarter last year
Operating cash flow −$5.7M +3.7% vs same quarter last year
Revenue by quarter
$149.3K
$50.3K
$162.9K
$145.4K
$263.9K
$146K
$166.1K
$282.9K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$622.5K−$47M
FY24$3.9M−$38M
FY23$6.8M−$35.3M
FY22$34.2M−$14.2M
FY21$97.9M$36.7M
FY20$74.6M$42.5M
FY19$215K−$6.2M
FY18$39.9K−$6.3M
FY17$7.7K−$7M
FY16-−$1.9M
FY15--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100000%−75000%−50000%−25000%0%25000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2564.3%−8058.8%−7550.3%
FY2474.5%−1023.7%−970.6%
FY2338.6%−626.9%−518.7%
FY2284%−78.8%−41.6%
FY2188.2%47.1%37.5%
FY2077.7%55.9%57%
FY1947.7%−2741.6%−2882%
FY1876.5%−15328.6%−15714.3%
FY1796.1%−59567.6%−90827.9%
FY16---
FY15---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$20M$0$20M$40M$60MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$29.8M
FY24−$29.9M
FY23−$23.4M
FY22$5.1M
FY21$40.4M
FY20$27.4M
FY19−$5.6M
FY18−$4.1M
FY17−$3.3M
FY16−$1.3M
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Co-Diagnostics
  • Healthcare median
−100000%−75000%−50000%−25000%0%25000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearCo-DiagnosticsHealthcare median
FY25−7550.3%−30.6%
FY24−970.6%−47%
FY23−518.7%−58%
FY22−41.6%−80.4%
FY2137.5%−71.8%
FY2057%−62.2%
FY19−2882%−46.2%
FY18−15714.3%−49.6%
FY17−90827.9%−45.9%
FY16-−36%
FY15-−37.8%